Authors
Latest:
Dr. Modi on Trastuzumab Deruxtecan in HER2-low Breast CancerShanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for FellowsInvestigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Latest:
Testing for PSMA in Community SettingsScott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.
Latest:
Research on CAR T Therapy in Earlier Lines of TreatmentAmit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.
Latest:
Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHLEvandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.
Latest:
Dr. DeCaprio on Raising Awareness in Merkel Cell CarcinomaJames A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.
Latest:
Dr. Ahn on Choosing Between Treatment Options in CLLInhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.
Latest:
Summary of Unmet Needs and Future Directions in MDSExperts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.
Latest:
Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid TumorsAurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.
Latest:
Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CISKarim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.
Latest:
Dr. Vaishampayan on the Rationale of the PROBE Trial in RCCUlka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.
Latest:
Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic CancerWen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.
Latest:
GvHD: Advice for PatientsExperts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.
Latest:
Future Treatment Landscape of AMLCorey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Latest:
Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLCDavid Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
Latest:
Evolving Treatment Landscape of HER2+ Metastatic Breast CancerClosing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.
Latest:
Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast CancerGretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.
Latest:
ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment LandscapeFollowing the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Latest:
Dr. Mercado on Evolution of Biopsy Techniques in Lung CancerJorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.
Latest:
Dr. Labaki on Disparities in Mammography Screenings During the COVID-19 PandemicChris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.
Latest:
Prostate Cancer Imaging: Unmet Needs and Knowledge GapsMedical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.
Latest:
Dr. Nair on Using Yoga to Improve Quality of Life in Patients Undergoing Breast Cancer TreatmentsNita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.
Latest:
Dr. Botta on the Diagnosis and Treatment of ESCCGregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.
Latest:
Groundbreaking Grant to John Theurer Cancer Center Will Establish the Hennessy Institute for Cancer Prevention and Applied Molecular MedicineThe family of Mike and Patti Hennessy made a transformational gift in their memory to establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine.
Latest:
HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges RemainRoadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.
Latest:
Emerging Agents and Future of Small Cell Lung CancerJared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.
Latest:
Dr. Schulte on the PRECISION 1 Trial of Nab-Sirolimus in TSC1/2-Mutated Solid TumorsBrian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.
Latest:
Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast CancerWilliam Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.
Latest:
Dr. Corr on the Utilization of Molecular Profiling in Endometrial CancerBradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.
